![Teva Pharmaceuticals Recalls Acute Myeloid Leukemia Drug Over Particulate Matter Contamination - Top Class Actions Teva Pharmaceuticals Recalls Acute Myeloid Leukemia Drug Over Particulate Matter Contamination - Top Class Actions](https://s40123.pcdn.co/wp-content/uploads/2022/03/recallTeva.jpg.optimal.jpg)
Teva Pharmaceuticals Recalls Acute Myeloid Leukemia Drug Over Particulate Matter Contamination - Top Class Actions
![Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News](https://s.abcnews.com/images/US/teva-pharma-2-gty-ps-221103_1667481193658_hpMain_16x9_1600.jpg)
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
![Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges | CNN Business Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges | CNN Business](https://media.cnn.com/api/v1/images/stellar/prod/230821162715-teva-pharmaceuticals-file-restricted.jpg?c=16x9&q=h_720,w_1280,c_fill)
Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges | CNN Business
![Teva Pharmaceuticals Announces Launch of Daily Maintenance Asthma Medication | Asthma and Allergy Foundation of America Teva Pharmaceuticals Announces Launch of Daily Maintenance Asthma Medication | Asthma and Allergy Foundation of America](https://community.aafa.org/fileSendAction/fcType/0/fcOid/510642830861510679/filePointer/510642830861510701/fodoid/510642830861510696/imageType/MEDIUM/inlineImage/true/Teva-announced-launch-of-new-daily-asthma-medicine.png)
Teva Pharmaceuticals Announces Launch of Daily Maintenance Asthma Medication | Asthma and Allergy Foundation of America
![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678526/5/AJOVY+Image.jpg?download=1)